BD Announces FDA 510(k) Clearance Of Two-Hour Test To Identify Superbug In Patients With Positive Blood Cultures

BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced that it received clearance from the U.S. Food and Drug Administration (FDA) for the BD GeneOhm(TM) StaphSR assay. This new assay is the first test available to rapidly and simultaneously identify two deadly healthcare-associated infections (HAIs) — Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) — from patients with positive blood cultures. [click link for full article]

More: continued here

Filed under: MRSA / Drug Resistance on January 4th, 2008